ERICA INGRAM: Open Payments
NPI 1306117692 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$649 in 29 payments from 13 companies in 2025. Trend: 2023 $1,610 · 2024 $1,347 · 2025 $649
Food & beverage: $649
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $147 |
| Lundbeck LLC | 5 | $109 |
| Supernus Pharmaceuticals, Inc. | 5 | $87 |
| Alkermes, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Vertical Pharmaceuticals, LLC | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
Products named: CAPLYTA, REXULTI, Qelbree, ARISTADA, HETLIOZ, SPRAVATO, ABILIFY MAINTENA, Relexxii.
Industry payments across MD — which companies pay providers there.
